The Targeting Acute Congestion with Tolvaptan in Congestive Heart Failure Study: A Randomized, Double blind, Placebo-controlled Trial in Acute Heart Failure
Presented by Robert Mentz, MD Durham, NC
Hemodynamic Monitoring in Advanced Heart Failure: Results from the LAPTOP-HF Trial
Presented by William Abraham, MD, Columbus, OH
PRIMA II: Can NT-proBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions? An international, multicenter, randomized clinical trial.
Presented by Susan Stienen, MD, Amsterdam, Netherlands
Two other late breaking trial will be discussed as well.
The Late Breaking Clinical Trial session is one of the most popular session of this four day meeting, with overall expected attendance of over 2000 physicians, research scientists, advanced practice nurses and PharmD's.
In the United States, approximately 5.7 million patients aged ≥20 years have HF, with 870,000 new cases diagnosed each year (data from 2005 to 2011). The American Heart Association estimates that the 2012 total cost for HF was $30.7 billion, of which 68% was due to direct medical costs. That cost is expected to increase to $70 billion by 2030.
The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. HFSA supports a multi-disciplinary clinical team approach for the preventions of and care for heart failure patients and is seeking to raise awareness about this devastating disease
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/late-breaking-clinical-trial-session-at-hfsa-20th-annual-scientific-meeting-300328446.html
SOURCE Heart Failure Society of America